CN Bio has introduced two new animal microphysiological system (MPS) models to its contract research services (CRS) that it hopes will enhance translatability in preclinical drug safety and toxicology assessments.  Building upon its drug induced liver injury (DILI) assay, the company says the expanded offering enables rapid, comparative studies between commonly used animal and human […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!